Osocimab, formerly known as BAY 1213790, represents a novel monoclonal protein currently undergoing clinical assessment for the treatment of several hematologic tumors. This molecule primarily targets CD38, a surface https://harleyvpnw329194.aboutyoublog.com/52368655/osocimab-a-deep-analysis-into-bay-1213790-and-its-promise